Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.69 |
| ▸ | TERT | O14746 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154394 | 0.92 | KDM1A (0.84) | KDM1AKMT2AMEN1LMNAACHE | |
| SCHEMBL17154363 | 0.91 | KDM1A (0.58) | KDM1ATERTMDM4KMT2ALMNA | |
| SCHEMBL31312578 | 0.86 | KDM1A (0.64) | KDM1ATERT | |
| SCHEMBL3366281 | 0.83 | KDM1A (0.66) | KDM1ATERTKMT2ALMNAKDR | |
| SCHEMBL17154450 | 0.81 | KDM1A (1.00) | KDM1AKMT2AMEN1LMNAACHE | |
| SCHEMBL17154448 | 0.80 | KMT2A (0.62) | KDM1ATERTKMT2AMEN1ACHE | |
| SCHEMBL17154449 | 0.79 | HTT (0.51) | KDM1AKMT2ALMNAHTTPOLB | |
| SCHEMBL17154399 | 0.78 | KDM1A (0.62) | KDM1AKMT2AMEN1LMNAACHE | |
| SCHEMBL31237457 | 0.78 | KDM1A (0.78) | KDM1AKMT2ALMNAKCNH2TOP2A | |
| SCHEMBL17154366 | 0.76 | KMT2A (0.60) | KDM1AKMT2AMEN1ACHEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | MiRx Pharmaceuticals, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2015153535-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MiRx Pharmaceuticals, LLC (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | TP53, DDX3X, API5 | KDM1A 702/4885TERT 1110/4885MDM4 4/4885 |
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | TP53, MDM4, MDM2 | KDM1A 650/4885TERT 1268/4885MDM4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.